Stock & Company Details
Delcath Systems Inc $DCTH
Price:
N/A
N/A
35M
$522M
52 Week High:
N/A
10 Day Average Volume:
N/A
2465.57
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
DCTH technical indicators
Latest Delcath Systems Inc (DCTH) indicator readings as of 2026-10-09.
DCTH's 14-day RSI is 45.2, in neutral territory. At $15.36 it is trading 27.9% above its 200-day moving average of $12.01, and below its 50-day average of $15.94. Price sits in the middle of its Bollinger Bands ($15.01 to $16.65). ADX reads 18.2, indicating a range-bound market rather than a trend.
Overview
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Finance Bot
Ask your questions
Start by typing a question below.
